Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac Dysfunction
Carlo G. Tocchetti(Federico II University Hospital), Nicola Maurea(Cancer Institute (WIA)), Claudio Arra(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Fabio Di Lisa(University of Padua), Giovanna Piscopo(University of Cagliari), Carmela Coppola, Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Antonella Arcari(Istituto Neurologico Mediterraneo), Andrea Carpi(European Institute of Oncology), Clemente Cipresso(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenica Rea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M. Monti(Federico II University Hospital), Cristina Quintavalle(Institute for Experimental Endocrinology and Oncology), Gerolama Condorelli(Institute for Experimental Endocrinology and Oncology), Marika Campesan(University of Padua)
Cited by 92
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal - Cardiovascular Imaging|2022|486
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2020|364